Full text is available at the source.
Efficacy of Temozolomide Is Correlated With 1p Loss and Methylation of the Deoxyribonucleic Acid Repair Gene MGMT in Malignant Gliomas
Temozolomide works better in malignant brain tumors with 1p gene loss and MGMT gene methylation
AI simplified
Abstract
Promoter methylation of the MGMT gene is associated with improved outcomes in 44 patients with recurrent malignant gliomas treated with temozolomide.
- MGMT promoter methylation correlates positively with clinical response to temozolomide therapy.
- Loss of heterozygosity (LOH) of 1p and 19q is associated with better responses to treatment.
- Patients with LOH of 1p and MGMT promoter methylation may experience longer progression-free survival.
- The findings suggest that LOH of 1p could be an important predictor of treatment outcomes alongside MGMT methylation.
AI simplified